Idexx Laboratories (IDXX) revenue: $4.3B
Idexx Laboratories reported $4.3B of revenue for the year ended Dec 31, 2025, up 10.4% from $3.9B a year earlier.
From Idexx Laboratories's filings with the SEC · Read the filing · IDXX stock page
Idexx Laboratories revenue by year
#778 of 3,622 US companies by revenue · See the full ranking
| Year ended | Revenue | Change |
|---|---|---|
| Dec 31, 2025 | $4.3B | +10% |
| Dec 31, 2024 | $3.9B | +6% |
| Dec 31, 2023 | $3.7B | +9% |
| Dec 31, 2022 | $3.4B | +5% |
| Dec 31, 2021 | $3.2B | – |
Revenue of similar companies
Companies in the same industry as Idexx Laboratories, by SEC industry code, with the closest revenue. Each name opens the same page for that company.
| Company | Revenue, latest year | Year ended |
|---|---|---|
| BeOne Medicines | $5.3B | Dec 31, 2025 |
| Elanco Animal Health | $4.7B | Dec 31, 2025 |
| Idexx Laboratories | $4.3B | Dec 31, 2025 |
| Jazz Pharmaceuticals | $4.3B | Dec 31, 2025 |
| PERRIGO | $4.3B | Dec 31, 2025 |
| Alnylam Pharmaceuticals | $3.7B | Dec 31, 2025 |
| Biomarin Pharmaceutical | $3.2B | Dec 31, 2025 |
Questions and answers
What is Idexx Laboratories's revenue?
Idexx Laboratories reported $4.3B of revenue for the year ended Dec 31, 2025, up 10.4% from $3.9B a year earlier.
Numbers as reported in Idexx Laboratories's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology